Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 Pretax Margin % is 6.87% as of Mar. 2026, which is 36% below its 10-year median of 10.68. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Novogene Co ranks better than 78.87% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Novogene Co's Pre-Tax Income for the
three
months ended in Mar. 2026 was ¥38 Mil. Novogene Co's Revenue for the
three
months ended in Mar. 2026 was ¥556 Mil. Therefore, Novogene Co's pretax margin for the quarter that ended in Mar. 2026 was 6.87%.
The historical rank and industry rank for Novogene Co's Pretax Margin % or its related term are showing as below:
SHSE:688315'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.38 Med: 10.68 Max: 13.21
Current: 8.5
SHSE:688315's Pretax Margin % is ranked better than 78.87% of 942
companies
in the Biotechnology industry
Industry Median: -89.895
vs SHSE:688315: 8.50
Novogene Co (SHSE:688315) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Novogene Co Pretax Margin % Related Terms
Novogene Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Novogene Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Novogene Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Novogene Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novogene Co (SHSE:688315) has a Pretax Margin % of 6.87% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novogene Co and its competitors. This is 36% below median its historical median of 10.68. Over the past decade, Novogene Co's Pretax Margin % has ranged from 2.38 to 13.21. According to the industry distribution chart, Novogene Co ranks #199 out of 942 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Novogene Co's Pretax Margin % too high?
Novogene Co's current Pretax Margin % of 6.87% is 36% below median its 10-year median of 10.68. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 13.21. Based on the distribution chart, Novogene Co ranks #199 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #199 out of 942 companies for Pretax Margin %. This places Novogene Co in the top 21% of its industry — outperforming the majority of peers. Historically, Novogene Co's own Pretax Margin % has ranged from 2.38 to 13.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novogene Co and its competitors. Novogene Co's current Pretax Margin % is 6.87%, which is 36% below median its own 10-year median of 10.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current Pretax Margin % is 6.87%, which is 36% below median its 10-year median of 10.68. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Pretax Margin % is 6.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
Pretax Margin %: 6.87% (36% below median its 10-year median of 10.68)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
